User:Mr. Ibrahem/Durvalumab

Durvalumab, sold under the brand name Imfinzi, is a medication used to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Specifically it is used for cases that produce a protein known as PD-L1. It is given by injection into a vein every two weeks.

Common side effects include cough, tiredness, pneumonitis, hair loss, shortness of breath, nausea, and rash. Other side effects may include immune-mediated damage. Use in pregnancy may harm the baby. It is a monoclonal antibody that attaches to and blocking programmed death-ligand 1 (PD-L1). This results in the immune system being able to attack the cells in question.

Durvalumab was approved for medical use in the United States in 2017 and Europe in 2018. In the United Kingdom 500 mg costs the NHS about £2,500 as of 2021. This amount in the United States costs about US$3,900.